Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2021 | 12-2020 | 09-2020 | 06-2020 | 03-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 1,793,000 | 4,495,000 | 2,333,000 | 1,101,000 | 564,000 |
| Depreciation Amortization | 934,000 | 3,327,000 | 2,461,000 | 1,653,000 | 828,000 |
| Accounts receivable | 165,000 | -924,000 | -343,000 | 127,000 | -104,000 |
| Other Working Capital | -372,000 | -892,000 | -1,181,000 | -860,000 | -541,000 |
| Other Operating Activity | 117,000 | 1,895,000 | 833,000 | 16,000 | -32,000 |
| Operating Cash Flow | $2,637,000 | $7,901,000 | $4,103,000 | $2,037,000 | $715,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -14,000 | N/A | -15,000 | -32,000 | N/A |
| PPE Investments | -397,000 | -2,177,000 | -1,498,000 | -1,002,000 | -360,000 |
| Net Acquisitions | -15,000 | 16,000 | 16,000 | 16,000 | N/A |
| Purchase Of Investment | N/A | -83,000 | N/A | N/A | N/A |
| Sale Of Investment | N/A | 10,000 | N/A | N/A | -36,000 |
| Other Investing Activity | 4,000 | 19,000 | 13,000 | 6,000 | 3,000 |
| Investing Cash Flow | $-422,000 | $-2,215,000 | $-1,484,000 | $-1,012,000 | $-393,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 24,000 | 2,000 | 3,000 | 31,000 | 51,000 |
| Debt Issued | N/A | 1,281,000 | 1,280,000 | 1,279,000 | N/A |
| Debt Repayment | -2,000 | -1,333,000 | -1,332,000 | -2,000 | -1,000 |
| Common Stock Issued | 86,000 | 245,000 | 229,000 | 146,000 | 89,000 |
| Common Stock Repurchased | -275,000 | -403,000 | -242,000 | -240,000 | -236,000 |
| Dividend Paid | -800,000 | -2,560,000 | -1,919,000 | -1,280,000 | -638,000 |
| Other Financing Activity | 0 | -11,000 | -11,000 | -11,000 | 0 |
| Financing Cash Flow | $-967,000 | $-2,779,000 | $-1,992,000 | $-77,000 | $-735,000 |
| Exchange Rate Effect | -32,000 | 71,000 | -7,000 | -45,000 | -70,000 |
| Beginning Cash Position | 6,838,000 | 3,860,000 | 3,860,000 | 3,860,000 | 3,860,000 |
| End Cash Position | 8,054,000 | 6,838,000 | 4,480,000 | 4,763,000 | 3,377,000 |
| Net Cash Flow | $1,216,000 | $2,978,000 | $620,000 | $903,000 | $-483,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 2,637,000 | 7,901,000 | 4,103,000 | 2,037,000 | 715,000 |
| Capital Expenditure | -397,000 | -2,177,000 | -1,498,000 | -1,002,000 | -360,000 |
| Free Cash Flow | 2,240,000 | 5,724,000 | 2,605,000 | 1,035,000 | 355,000 |